Chu Guangdi, Ji Xiaoyu, Wang Yonghua, Niu Haitao
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Department of Gynecology Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Mol Ther Nucleic Acids. 2023 Jun 5;33:110-126. doi: 10.1016/j.omtn.2023.06.001. eCollection 2023 Sep 12.
Muscle-invasive urothelial cancer (MUC), characterized by high aggressiveness and significant heterogeneity, is currently lacking highly precise individualized treatment options. We used a computational pipeline to synthesize multiomics data from MUC patients using 10 clustering algorithms, which were then combined with 10 machine learning algorithms to identify molecular subgroups of high resolution and develop a robust consensus machine learning-driven signature (CMLS). Through multiomics clustering, we identified three cancer subtypes (CSs) that are related to prognosis, with CS2 exhibiting the most favorable prognostic outcome. Subsequent screening enabled identification of 12 hub genes that constitute a CMLS with robust predictive power for prognosis. The low-CMLS group exhibited a more favorable prognosis and greater responsiveness to immunotherapy and was more likely to exhibit the "hot tumor" phenotype. The high-CMLS group had a poor prognosis and lower likelihood of benefitting from immunotherapy, but dasatinib and romidepsin may serve as promising treatments for them. Comprehensive analysis of multiomics data can offer important insights and further refine the molecular classification of MUC. Identification of CMLS represents a valuable tool for early prediction of patient prognosis and for screening potential candidates likely to benefit from immunotherapy, with broad implications for clinical practice.
肌肉浸润性尿路上皮癌(MUC)具有高侵袭性和显著异质性的特点,目前缺乏高度精确的个体化治疗方案。我们使用了一个计算流程,通过10种聚类算法来整合MUC患者的多组学数据,然后将其与10种机器学习算法相结合,以识别高分辨率的分子亚组,并开发出一种强大的基于机器学习的共识特征(CMLS)。通过多组学聚类,我们确定了三种与预后相关的癌症亚型(CSs),其中CS2的预后结果最为良好。随后的筛选确定了12个核心基因,这些基因构成了对预后具有强大预测能力的CMLS。低CMLS组预后更佳,对免疫治疗的反应性更高,且更有可能表现出“热肿瘤”表型。高CMLS组预后较差,从免疫治疗中获益的可能性较低,但达沙替尼和罗米地辛可能是对其有前景的治疗方法。对多组学数据的综合分析可以提供重要见解,并进一步完善MUC的分子分类。CMLS的识别是早期预测患者预后以及筛选可能从免疫治疗中获益的潜在候选者的有价值工具,对临床实践具有广泛意义。